デフォルト表紙
市場調査レポート
商品コード
1413033

分子腫瘍診断薬市場:製品、技術、がんタイプ、エンドユーザー別-2024-2030年の世界予測

Molecular Oncology Diagnostics Market by Product (Instruments, Reagents), Technology (Chips & Microarrays, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology (INAAT)), Cancer Type, End User - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 180 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.54円
分子腫瘍診断薬市場:製品、技術、がんタイプ、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 180 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

分子腫瘍診断薬市場規模は2023年に88億4,000万米ドルと推計され、2024年には98億8,000万米ドルに達し、CAGR 11.83%で2030年には193億6,000万米ドルに達すると予測されます。

分子腫瘍診断薬の世界市場

主な市場の統計
基準年[2023] 88億4,000万米ドル
予測年[2024] 98億8,000万米ドル
予測年 [2030] 193億6,000万米ドル
CAGR(%) 11.83%
分子腫瘍診断薬 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは分子腫瘍診断薬市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、分子腫瘍診断薬市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1-市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1-分子腫瘍診断薬市場の市場規模および予測は?

2-分子腫瘍診断薬市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3-分子腫瘍診断薬市場における技術動向と規制の枠組みは?

4-分子腫瘍診断薬市場における主要ベンダーの市場シェアは?

5-分子腫瘍診断薬市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • がんの罹患率の増加と人口の高齢化
      • 自動化された高度な診断技術に対するニーズの高まり
      • 有利な医療償還と個別化医療への傾向
    • 抑制要因
      • 分子腫瘍診断薬テストに関連する高コスト
    • 機会
      • 腫瘍診断における研究開発活動への継続的な投資
      • 分子生物学とバイオテクノロジーにおける技術の進歩
    • 課題
      • 厳しい規制のハードルと分子診断技術における一貫した基準の欠如
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 分子腫瘍診断薬市場:製品別

  • 機器
  • 試薬

第7章 分子腫瘍診断薬市場:技術別

  • チップとマイクロアレイ
  • In situハイブリダイゼーション
  • 等温核酸増幅技術(INAAT)
  • 質量分析法
  • マルチプレックス
  • PCR
  • シーケンス
  • 転写媒介増幅

第8章 分子腫瘍診断薬市場がんの種類別

  • 血液がん
  • 乳がん
  • 子宮頸がん
  • 結腸直腸がん
  • 腎臓がん
  • 肝臓がん
  • 肺がん
  • 前立腺がん

第9章 分子腫瘍診断薬市場:エンドユーザー別

  • 診断センター
  • 病院

第10章 南北アメリカの分子腫瘍診断薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋地域の分子腫瘍診断薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの分子腫瘍診断薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ主要企業別の分析

第14章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • Bayer AG
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Biocartis NV
    • Biocept, Inc.
    • BIOMERIEUX SA
    • Danaher Corporation
    • DiaSorin Molecular LLC
    • Enzo Biochem, Inc.
    • F. Hoffmann-La Roche Ltd.
    • GenMark Saglik
    • Hologic, Inc.
    • Illumina, Inc.
    • Leica Biosystems Nussloch GmbH
    • Myriad Genetics, Inc.
    • NeoGenomics Laboratories
    • OncoCyte Corporation
    • PathAI, Inc.
    • Personal Genome Diagnostics Inc.
    • QIAGEN N.V.
    • Siemens AG
    • Sysmex Asia Pacific Pte Ltd.
    • Thermo Fisher Scientific Inc.
  • 主要な製品ポートフォリオ

第15章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET DYNAMICS
  • FIGURE 7. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 10. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 12. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 14. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 24. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 9. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CHIPS & MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY MULTIPLEX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TRANSCRIPTION MEDIATED AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 198. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 199. MOLECULAR ONCOLOGY DIAGNOSTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-5C6F41F5AFFB

[180 Pages Report] The Molecular Oncology Diagnostics Market size was estimated at USD 8.84 billion in 2023 and expected to reach USD 9.88 billion in 2024, at a CAGR 11.83% to reach USD 19.36 billion by 2030.

Global Molecular Oncology Diagnostics Market

KEY MARKET STATISTICS
Base Year [2023] USD 8.84 billion
Estimated Year [2024] USD 9.88 billion
Forecast Year [2030] USD 19.36 billion
CAGR (%) 11.83%
Molecular Oncology Diagnostics Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Molecular Oncology Diagnostics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Molecular Oncology Diagnostics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Molecular Oncology Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bayer AG, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biocartis NV, Biocept, Inc., BIOMERIEUX SA, Danaher Corporation, DiaSorin Molecular LLC, Enzo Biochem, Inc., F. Hoffmann-La Roche Ltd., GenMark Saglik, Hologic, Inc., Illumina, Inc., Leica Biosystems Nussloch GmbH, Myriad Genetics, Inc., NeoGenomics Laboratories, OncoCyte Corporation, PathAI, Inc., Personal Genome Diagnostics Inc., QIAGEN N.V., Siemens AG, Sysmex Asia Pacific Pte Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Molecular Oncology Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Instruments
    • Reagents
  • Technology
    • Chips & Microarrays
    • In Situ Hybridization
    • Isothermal Nucleic Acid Amplification Technology (INAAT)
    • Mass Spectrometry
    • Multiplex
    • PCR
    • Sequencing
    • Transcription Mediated Amplification
  • Cancer Type
    • Blood Cancer
    • Breast Cancer
    • Cervical Cancer
    • Colorectal Cancer
    • Kidney Cancer
    • Liver Cancer
    • Lung Cancer
    • Prostate Cancer
  • End User
    • Diagnostic Centers
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Molecular Oncology Diagnostics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Molecular Oncology Diagnostics Market?

3. What are the technology trends and regulatory frameworks in the Molecular Oncology Diagnostics Market?

4. What is the market share of the leading vendors in the Molecular Oncology Diagnostics Market?

5. Which modes and strategic moves are suitable for entering the Molecular Oncology Diagnostics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Molecular Oncology Diagnostics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer cases and aging population
      • 5.1.1.2. Rising need for automated and advanced diagnostic techniques
      • 5.1.1.3. Favorable health reimbursement and the trend toward personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with molecular oncology diagnostics test
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing investments in R&D activities in oncology diagnostics
      • 5.1.3.2. Technological advancements in molecular biology and biotechnology
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory hurdles coupled with a lack of consistent standards in molecular diagnostic techniques
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Molecular Oncology Diagnostics Market, by Product

  • 6.1. Introduction
  • 6.2. Instruments
  • 6.3. Reagents

7. Molecular Oncology Diagnostics Market, by Technology

  • 7.1. Introduction
  • 7.2. Chips & Microarrays
  • 7.3. In Situ Hybridization
  • 7.4. Isothermal Nucleic Acid Amplification Technology (INAAT)
  • 7.5. Mass Spectrometry
  • 7.6. Multiplex
  • 7.7. PCR
  • 7.8. Sequencing
  • 7.9. Transcription Mediated Amplification

8. Molecular Oncology Diagnostics Market, by Cancer Type

  • 8.1. Introduction
  • 8.2. Blood Cancer
  • 8.3. Breast Cancer
  • 8.4. Cervical Cancer
  • 8.5. Colorectal Cancer
  • 8.6. Kidney Cancer
  • 8.7. Liver Cancer
  • 8.8. Lung Cancer
  • 8.9. Prostate Cancer

9. Molecular Oncology Diagnostics Market, by End User

  • 9.1. Introduction
  • 9.2. Diagnostic Centers
  • 9.3. Hospitals

10. Americas Molecular Oncology Diagnostics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Molecular Oncology Diagnostics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Molecular Oncology Diagnostics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. FPNV Positioning Matrix
  • 13.2. Market Share Analysis, By Key Player
  • 13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

  • 14.1. Key Company Profiles
    • 14.1.1. Abbott Laboratories
    • 14.1.2. Agilent Technologies, Inc.
    • 14.1.3. Bayer AG
    • 14.1.4. Becton, Dickinson and Company
    • 14.1.5. Bio-Rad Laboratories, Inc.
    • 14.1.6. Biocartis NV
    • 14.1.7. Biocept, Inc.
    • 14.1.8. BIOMERIEUX SA
    • 14.1.9. Danaher Corporation
    • 14.1.10. DiaSorin Molecular LLC
    • 14.1.11. Enzo Biochem, Inc.
    • 14.1.12. F. Hoffmann-La Roche Ltd.
    • 14.1.13. GenMark Saglik
    • 14.1.14. Hologic, Inc.
    • 14.1.15. Illumina, Inc.
    • 14.1.16. Leica Biosystems Nussloch GmbH
    • 14.1.17. Myriad Genetics, Inc.
    • 14.1.18. NeoGenomics Laboratories
    • 14.1.19. OncoCyte Corporation
    • 14.1.20. PathAI, Inc.
    • 14.1.21. Personal Genome Diagnostics Inc.
    • 14.1.22. QIAGEN N.V.
    • 14.1.23. Siemens AG
    • 14.1.24. Sysmex Asia Pacific Pte Ltd.
    • 14.1.25. Thermo Fisher Scientific Inc.
  • 14.2. Key Product Portfolio

15. Appendix

  • 15.1. Discussion Guide
  • 15.2. License & Pricing